Emerging immune targets for the therapy of allergic asthma

Nature Reviews Drug Discovery

Volumn 1, Issue 1, 2002, Pages 55-64

  Corry, David B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CYTOKINE; EOSINOPHIL CATIONIC PROTEIN; FLUNISOLIDE; FORMOTEROL; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; JANUS KINASE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MAJOR BASIC PROTEIN; METHYLPREDNISOLONE; METHYLXANTHINE; MONOCLONAL ANTIBODY; MONTELUKAST; PREDNISONE; PROTEINASE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TRIAMCINOLONE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON; CYTOKINE RECEPTOR; PROTEIN TYROSINE KINASE;

ALLERGIC ASTHMA; ATOPY; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; DRUG INDUSTRY; DRUG TARGETING; EOSINOPHIL; EPIDEMIC; GOBLET CELL; HELPER CELL; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNE SYSTEM; INCIDENCE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE HOMING; MAST CELL; MEDICAL RESEARCH; PATHOGENESIS; PHYSICIAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; TH2 CELL; ASTHMA; IMMUNOLOGY; PHYSIOLOGY; TH1 CELL;

ASTHMA; CYTOKINES; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTORS, CYTOKINE; TH1 CELLS; TH2 CELLS;

EID: 0036051993     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd702     Document Type: Review

References (96)

1. Hartert, T. V. & Peebles, R. S. Jr. Epidemiology of asthma: the year in review. Curr. Opin. Pulm. Med. 6, 4-9 (2000).
2. Holgate, S. T. The epidemic of allergy and asthma. Nature 402, B2-B4 (1999).
3. Bousquet, J. Global Initiative for Asthma (GINA) and its objectives. Clin. Exp. Allergy 30, 2-5 (2000).
4. Lemanske, R. F. Jr & Busse, W. W. Asthma. J. Am. Med. Assoc. 278, 1855-1873 (1997).
5. Anonymous. Drugs for asthma. Med. Lett. Drugs Ther. 42, 19-24 (2000).
6. Wills-Karp, M. Immunologic basis at antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17, 255-281 (1999).
7. Corry, D. B. et al. Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice, Mol. Med. 4, 344-355 (1998).
8. Wills-Karp, M. et al. Interleukin-13: central mediator of allergic asthma. Science 282, 2258-2261 (1998).
9. Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma, Science 282, 2261-2263 (1998).
10. Obiri, N. I., Debinski, W., Leonard, W. J. & Puri, R. K. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the commony γ-chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J. Biol. Chem. 270, 8797-8804 (1995).
11. Lefort, S., Vita, N., Reeb, R., Caput, D. & Ferrara, P. IL-13 and IL-4 share signal transduction elements as well as receptor components in TF-1 cells. FEBS Lett. 366, 122-126 (1995).
12. Smerz-Bertling, C. & Duschl, A. Both interleukin 4 and interleukin 13 induce tyrosine phosphorylation of the 140-kDa subunit of the interleukin 4 receptor. J. Biol. Chem. 270, 966-970 (1995).
13. Murata, T. & Puri, R. K. Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells. Cell. Immunol. 175, 33-40 (1997).
14. Orchansky, P. L., Ayres, S. D., Hilton, D. J. & Schrader, J. W. An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4. J. Biol. Chem. 272, 22940-22947 (1997).
15. Palmer-Crocker, R. L., Hughes, C. C. & Pober, J. S. IL-4 and IL-13 activate the JAK2 tyrosine kinase and STAT6 in cultured human vascular endothelial cells through a common pathway that does not involve the γc chain. J. Clin. Invest. 98, 604-609 (1996).
16. Madden, K. B. et al. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal rnastocytosis. J. Immunol. 147, 1387-1391 (1991).
17. Finkelman, F. D. et al. IL-4 is required to generate and sustain in vivo IgE responses. J. Immunol. 141, 2335-2341 (1988).
18. Snapper, C. M., Finkelman, F. D. & Paul, W. E. Differential regulation of IgG1 and IgE synthesis by interleukin 4. J. Exp. Med. 167, 183-196 (1988).
19. Finkelman, F. D., Katona, I. M., Urban, J. F. Jr & Paul, W. E. Control of in vivo IgE production in the mouse by interleukin 4. Ciba Found. Symp. 147, 3-17; discussion 17-22 (1989).
20. Coffman, R. L., Seymour, B. W., Hudak, S., Jackson, J. & Rennick, D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 245, 308-310 (1989).
21. Abbas, A. K., Murphy, K. M. & Sher, A. Functional diversity of helper T lymphocytes. Nature 383, 787-793 (1996).
22. H 2 effector function. Proc. Natl Acad. Sci. USA 95, 6930-6935 (1998).
23. Mitcham, J. L. et al. T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family J. Biol. Chem. 271, 5777-5783 (1996).
24. + T cells: induction of type 2 cytolkine production by T1/ST2 cross-linking. J. Immunol. 166, 3143-3150 (2001).
25. H 2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J. Clin. Invest. 106, 551-559 (2000).
26. Coyle, A. J. et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190, 895-902 (1999).
27. Hoshino, K., et al, The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J. Exp. Med. 190, 1541-1548 (1999).
28. Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E. & McKenzie, A. N. T1/ST2-deficient mice demonstrate the importance at T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191, 1069-1076 (2000).
29. H 2 effector cells in experimental leishmaniasis. J. Immunol. 153, 4142-4148 (1994).
30. McArthur, J. G. & Raulet, D. H. CD28-induced costimulation at T helper type 2 cells mediated by induction of responsiveness to interleukin 4. J. Exp. Med. 178, 1645-1653 (1993).
31. Howland, K. C., Ausubel, L. J., London, C. A. & Abbas, A. K. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J. Immunol. 164, 4465-4470 (2000).
32. H 2 subsets in a murine model of asthma. Am. J. Respir. Cell Mol. Biol. 18, 453-462 (1998).
33. Keane-Myers, A., Gause, W. C., Linsley, P S., Chen, S. J. & Wills-Karp, M. B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens. J. Immunol. 158, 2042-2049 (1997).
34. Van Oosterhout, A. J. et al. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 17, 386-392 (1997).
35. Krinzman, S. J. et al. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J. Clin. Invest. 98, 2693-2699 (1996).
36. H 2 differentiation. J. Immunol. 163, 2634-2639 (1999).
37. Butcher, E. C. & Picker, L. J. Lymphocyte homing and homeostasis. Science 272, 60-66 (1996).
38. H 2 chemoattractant. Blood 92, 4036-4039 (1998).
39. H 1 cells. J. Immunol. 161, 547-551 (1998).
40. H 2 cytokines IL-4 and IL-13. J. Immunol. 161, 5027-5038 (1998).
41. Panina-Bordignon, P. et al. The CC chemokine receptors CCR4 and CCR8 identity airway T cells of allergen-challenged atopic asthmatics. J. Clin. Invest. 107, 1357-1364 (2001).
42. H and type 2 T cytotoxic cells in health and disease. Eur. J. Immunol. 30, 2972-2979 (2000).
43. H 2. J. Exp. Med. 193, 255-261 (2001).
44. H 2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404, 407-411 (2000).
45. Huang, D. R., Wang, J., Kivisakk, P., Rollins, B. J. & Ransohoff, R. M. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193, 713-726 (2001).
46. H 1) cytokine responses in CC chemokine receptor 2 knockout mice. J. Clin. Invest. 100, 2552-2561 (1997).
47. H 2 cytokines, B cell outgrowth, and sustained neutrophilic inflammation. J. Exp. Med. 192, 205-218 (2000).
48. MacLean, J. A. et al. CC chemokine receptor 2 is not essential for the development of antigen-induced pulmonary eosinophilia and airway hyperresponsiveness. J. Immunol. 165, 6568-6575 (2000).
49. + T cells. Immunity 11, 399-409 (1999).
50. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
51. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
52. Henderson, W. R. Jr, Chi, E. Y. & Maliszewski, C. R. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J. Immunol. 164, 1086-1095 (2000).
53. Borish, L. C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816-1823 (1999).
54. Borish, L. C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963-970 (2001).
55. Webb, D. C. et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J. Immunol. 165, 108-113 (2000).
56. Foster, P. S., Hogan, S. P., Ramsay, A. J., Matthael, K. I. & Young, I. G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183, 195-201 (1996).
57. Leckie, M. J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2144-2148 (2000).
58. Townsend, J. M. et al. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 13, 573-583 (2000).
59. Bauer, J. H., Liu, K. D., You, Y., Lai, S. Y. & Goldsmith, M. A. Heteromerization of the γc chain with the interleukin-9 receptor A-subunit leads to STAT activation and prevention of apoptosis. J. Biol. Chem. 273, 9255-9260 (1998).
60. Dirksen, U. et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common β-chain expression. J. Clin. Invest. 100, 2211-2217 (1997).
61. Izuhara, K. et al. Recent advances in understanding how interleukin 13 signals are involved in the pathogenesis of bronchial asthma. Arch. Immunol. Ther. Exp. (Warsz) Exp. 48, 505-512 (2000).
62. Grunewald, S. M. et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J. Immunol. 160, 4004-4009 (1998).
63. Dent, A. L., Hu-Li, J., Paul, W. E. & Staudt, L. M. T helper type 2 inflammatory disease in the absence of Interleukin 4 and transcription factor STAT6. Proc. Natl Acad. Sci. USA 95, 13823-13828 (1998).
64. H 2-type inflammation. Nature Genet. 16, 161-170 (1997).
65. H 2 cytokine gene expression in CD4 T cells. Cell 89, 587-596 (1997).
66. H 2 development and commitment. Immunity 12, 27-37 (2000).
67. Zhang, D. H. et al. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 11, 473-482 (1999).
68. H 2 differentiation in allergic airway inflammation. Nature Immunol. 2, 45-50 (2001).
69. Pandolfi, P. P. et al. Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nature Genet. 11, 40-44 (1995).
70. Russell, S. M. et al. Interaction of IL-2Rβ and γc chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266, 1042-1045 (1994).
71. Thomis, D. C. & Berg, L. J. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J. Exp. Med. 185, 197-206 (1997).
72. Oakes, S. A. et al. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity 5, 605-615 (1996).
73. Wang, L. H. et al. Selective disruption of interleukin 4 autocrine-regulated loop by a tyrosine kinase inhibitor restricts activity of T-helper 2 cells. Blood 95, 3816-3822 (2000).
74. Malabarba, M. G. et al. Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-γ and interleukin-4 receptor-α. Biochem. J. 319, 865-872 (1996).
75. Oshiba, A. et al. Passive transfer of immediate hypersensitivity and airway hyperresponsiveness by allergen-specific immunoglobulin (Ig)E and mice. J. Clin. Invest. 97, 1398-1408 (1996).
76. MacLean, J. A., Sauty, A., Luster, A. D., Drazen, J. M. & De Sanctis, G. T. Antigen-induced airway hyperresponsiveness, pulmonary eosinophilia, and chemokine expression in B cell-deficient mice. Am. J. Respir. Cell Mol. Biol. 20, 379-387 (1999).
77. Milgrom, H. et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N. Engl. J. Med. 341, 1966-1973 (1999).
78. Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184-190 (2001).
79. H 2 subset development in the absence of CD4. Immunity 6, 559-569 (1997).
80. Locksley, R. M., Reiner, S. L., Hatam, F., Littman, D. R. & Killeen, N. Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice. Science 261, 1448-1451 (1993).
81. Feito, M. J. et al. CD4 dependence of activation threshold and TCR signalling in mouse T lymphocytes. Scand. J. Immunol. 45, 166-174 (1997).
82. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
83. Kips, J. C. et al. Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice. Am. J. Respir. Crit. Care Med. 153, 535-539 (1996).
84. Hofstra, C. L. et al. Differential effects of endogenous and exogenous interferon-γ on immunoglobulin E, cellular infiltration, and airway responsiveness in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 19, 826-835 (1998).
85. H 2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J. Immunol. 164, 5575-5582 (2000).
86. Kline, J. N. et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160, 2555-2559 (1998).
87. Bliss, J. et al. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J. Immunol. 156, 887-894 (1996).
88. Bryan, S. A. et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2149-2153 (2000).
89. + T cells. Science 281, 1352-1354 (1998).
90. + T cell-intrinsic mechanism. J. Exp. Med. 188, 2289-2299 (1998).
91. Medzhitov, R. CpG DNA: security code for host defense. Nature Immunol. 2, 15-16 (2001).
92. Kreitman, R. J. et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345, 241-247 (2001).
93. Varga, L. V., Toth, S., Novak, I. & Falus, A. Antisense strategies: functions and applications in immunology. Immunol. Lett. 69, 217-224 (1999).
94. Nielsen, P. E. Peptide nucleic acids: on the road to new gene therapeutic drugs. Pharmacol. Toxicol. 86, 3-7 (2000).
95. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
96. Lehrman, S. Virus treatment questioned after gene therapy death. Nature 401, 517-518 (1999).